The Serum Institute of India (SII) has prepared 4 million doses of the new coronavirus vaccine. “IBS has already manufactured 40 million doses of the vaccine, under DCGI’s manufacturing and storage at risk license,” the company said in a statement. The SII, with the help of the Indian Council of Medical Research (ICMR), will seek early availability of this product for India.
Previously in an interview with mintSerum Institute Executive Director Adar Poonawalla said a vaccine against the coronavirus disease is likely to be available in the country in January 2021 as long as approvals from regulatory bodies are in place on time.
“Based on the success of the trials in India and the UK, and if regulatory approvals are in place on time, then we can expect the vaccine to be available in India in January 2021, only if it is immunogenic. and proven effective. Poonawalla had said.
The IBS and ICMR announced the completion of phase 3 clinical trial enrollment for the new coronavirus vaccine, Covishield, in India. Currently, the IBS and ICMR are conducting a phase 2/3 clinical trial of Covishield at 15 different centers across the country.
Covishield has been developed in the SII Pune laboratory with a master seed from the University of Oxford / Astra Zeneca. The UK-made vaccine is currently being tested in large efficacy trials in the UK, Brazil, South Africa and the US.
Meanwhile, India’s Covid-19 case burden rose to 86,83,916, according to data from the Union Ministry of Health. The death toll from coronavirus rose to 1.28,121, while the number of people who have recovered from the disease has risen to 80.66,501. The number of active cases remained below 5 lakh for the second day in a row.
.
